Erratum to Therapeutic effect of topical adiponectin in a mouse model of desiccating stress-induced dry eye (Invest Ophthalmol Vis Sci. (2013), 54, (155-162), 10.1167/iovs.12-10648);Therapeutic effect of topical adiponectin in a mouse model of desiccating stress-induced dry eye

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 1, 2013, Pages 155-162

  Li, Zhengri ^a   Woo, Je Moon ^b   Chung, Su Wol ^c   Kwon, Min Young ^c   Choi, Ji Suk ^a   Oh, Han Jin ^a   Yoon, Kyung Chul ^a  

^a Chonnam National University Medical School   (South Korea)

^b Ulsan University College of Medicine   (South Korea)

^c University of Ulsan   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; CD4 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CXCL9 CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; ADIPONECTIN RECEPTOR; ADIPONECTIN RECEPTOR 1, MOUSE; ADIPONECTIN RECEPTOR 2, MOUSE; ADIPOQ PROTEIN, MOUSE; CYTOKINE; EYE DROPS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CONJUNCTIVA; CONTROLLED STUDY; CORNEA; DISEASE SEVERITY; DRY EYE; EYE DROPS; FEMALE; FLOW CYTOMETRY; GOBLET CELL; IMMUNOHISTOCHEMISTRY; LACRIMAL GLAND FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; VISUAL SYSTEM PARAMETERS; ANIMAL; C57BL MOUSE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; LACRIMAL APPARATUS; LACRIMAL FLUID; METABOLISM; PHYSIOLOGICAL STRESS; PHYSIOLOGY; TOPICAL DRUG ADMINISTRATION;

ADIPONECTIN; ADMINISTRATION, TOPICAL; ANIMALS; CONJUNCTIVA; CORNEA; CYTOKINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRY EYE SYNDROMES; FEMALE; LACRIMAL APPARATUS; MICE; MICE, INBRED C57BL; OPHTHALMIC SOLUTIONS; RECEPTORS, ADIPONECTIN; STRESS, PHYSIOLOGICAL; TEARS;

MLCS; MLOWN;

EID: 84874518098     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10648a     Document Type: Erratum

References (63)

1. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136:318-326.
2. Stern ME, Pflugfelder SC. Inflammation in dry eye. Ocul Surf. 2004;2:124-130.
3. Pflugfelder SC, de Paiva CS, Li DQ, Stern ME. Epithelialimmune cell interaction in dry eye. Cornea. 2008;27:S9-11.
4. Pflugfelder SC, Stern ME; Symposium participants. Immunoregulation on the ocular surface: 2nd Cullen Symposium. Ocul Surf. 2009;7:67-77.
5. Yoon KC, De Paiva CS, Qi H, et al. Expression of Th-1 chemokines and chemokine receptors on the ocular surface of C57BL/6 mice: effects of desiccating stress. Invest Ophthalmol Vis Sci. 2007;48:2561-2569.
6. Yoon KC, Park CS, You IC, et al. Expression of CXCL9,-10,-11, and CXCR3 in the tear film and ocular surface of patients with dry eye syndrome. Invest OphthalmolVis Sci. 2010;51:643-650.
7. Behrens A, Doyle JJ, Stern L, et al. Dysfunctional tear syndrome study group. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea. 2006;25:900-907.
8. Gupta H, Jain S, Mathur R, et al. Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system. Drug Deliv. 2007;14:507-515.
9. Palmer SL, Bowen PA II, Green K. Tear flow in cyclosporine recipients. Ophthalmology. 1995;102:118-121.
10. Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000;47:119-125.
11. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004;137:337-342.
12. Prabhasawat P, Tseng SC. Frequent association of delayed tear clearance in ocular irritation. Br J Ophthalmol. 1998;82:666-675.
13. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology. 1999;106:811-816.
14. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79-83.
15. Statnick MA, Beavers LS, Conner LJ, et al. Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with type 2 diabetes. Int J Exp Diabetes Res. 2000;1:81-88.
16. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100:2473-2476.
17. Matsuda M, Shimomura I, Sata M, et al. Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem. 2002;277:37487-37491.
18. Wolf AM, Wolf D, Rumpold H, et al. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun. 2004;323:630-635.
19. Wulster-Radcliffe MC, Ajuwon KM, Wang J, et al. Adiponectin differentially regulates cytokines in porcine macrophages. Biochem Biophys Res Commun. 2004;316:924-929.
20. Neumeier M, Weigert J, Scḧaffler A, et al. Different effects of adiponectin isoforms in human monocytic cells. J Leukoc Biol. 2006;79:803-808.
21. Okamoto Y, Folco EJ, Minami M, et al. Adiponectin inhibits the production of CXC receptor 3 chemokine ligands in macrophages and reduces T-lymphocyte recruitment in atherogenesis. Circ Res. 2008;102:218-225.
22. Chung CP, Long AG, Solus JF, et al. Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus. 2009;18:799-806.
23. Katsiougiannis S, Kapsogeorgou EK, Manoussakis MN, et al. Salivary gland epithelial cells: a new source of the immunoregulatory hormone adiponectin. Arthritis Rheum. 2006;54: 2295-2299.
24. Ebina K, Fukuhara A, Ando W, et al. Serum adiponectin concentrations correlate with severity of rheumatoid arthritis evaluated by extent of joint destruction. Clin Rheumatol. 2009;28:445-451.
25. Lyzogubov VV, Tytarenko RG, Thotakura S, et al. Inhibition of new vessel growth in mouse model of laser-induced choroidal neovascularization by adiponectin peptide II. Cell Biol Int. 2009;33:765-771.
26. De Paiva CS, Corrales RM, Villarreal AL, et al. Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res. 2006;83:526-535.
27. De Paiva CS, Villarreal AL, Corrales RM, et al. Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferon-gamma. Invest Ophthalmol Vis Sci. 2007;48:2552-2560.
28. Niederkorn JY, Stern ME, Pflugfelder SC, et al. Desiccating stress induces T cell-mediated Sjögren's syndrome-like lacrimal keratoconjunctivitis. J Immunol. 2006;176:3950-3957.
29. YoonKC, De Paiva CS, Chen Z, et al. Desiccating environmental stress exacerbates autoimmune lacrimal keratoconjunctivitis in non-obese diabetic mice. J Autoimmun. 2008;30:212-221.
30. Villareal AL, Farley W, Pflugfelder SC. Effect of topical ophthalmic epinastine and olopatadine on tear volume in mice. Eye Contact Lens. 2006;32:272-276.
31. De Paiva CS, Corrales RM, Villarreal AL, et al. Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline. Invest Ophthalmol Vis Sci. 2006;47:2847-2856.
32. Yoon KC, Ahn KY, Choi W, et al. Tear production and ocular surface changes in experimental dry eye after elimination of desiccating stress. Invest Ophthalmol Vis Sci. 2011;52:7267-7273.
33. Yoon KC, Heo H, Kang IS, et al. Effect of topical cyclosporine A on herpes stromal keratitis in a mouse model. Cornea. 2008; 27:454-460.
34. Scherer PE, Williams S, Fogliano M, et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem. 1995;270:26746-26749.
35. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adiposespecific gene dysregulated in obesity. J Biol Chem. 1996;271: 10697-10703.
36. Shapiro L, Scherer PE. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol. 1998;8:335-338.
37. Di{dotless}éz JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003;148:293-300.
38. Waki H, Yamauchi T, Kamon J, et al. Impaired multimerization of human adiponectin mutants associated with diabetes: molecular structure and multimer formation of adiponectin. J Biol Chem. 2003;278:40352-40363.
39. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A. 2001;98:2005-2010.
40. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423:762-769.
41. Hug C, Wang J, Ahmad NS, et al. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A. 2004;101:10308-10313.
42. Lord E, Ledoux S, Murphy BD, et al. Expression of adiponectin and its receptors in swine. J Anim Sci. 2005;83:565-578.
43. Tang CH, Chiu YC, Tan TW, et al. Adiponectin enhances IL-6 production in human synovial fibroblast via an AdipoR1 receptor, AMPK, p38, and NF-kappa B pathway. J Immunol. 2007;179:5483-5492.
44. Toussirot E, Gaugler B, Bouhaddi M. Elevated adiponectin serum levels in women with systemic autoimmune diseases. Mediators Inflamm. 2010;2010:938408.
45. Katsiougiannis S, Tenta R, Skopouli FN, et al. Activation of AMP-activated protein kinase by adiponectin rescues salivary gland epithelial cells from spontaneous and interferon-gammainduced apoptosis. Arthritis Rheum. 2010;62:414-419.
46. Stern ME, Siemasko KF, Gao J, et al. Evaluation of ocular surface inflammation in the presence of dry eye and allergic conjunctival disease. Ocul Surf. 2005;3:S161-S164.
47. Niederkorn JY, Stern ME, Pflugfelder SC, et al. Desiccating stress induces T cell-mediated Sjögren's syndrome-like lacrimal keratoconjunctivitis. J Immunol. 2006;176:3950-3957.
48. Yoon KC, Jeong IY, Park YG, et al. Interleukin-6 and tumor necrosis factor-alpha levels in tears of patients with dry eye syndrome. Cornea. 2007;26:431-437.
49. De Paiva CS, Villarreal AL, Corrales RM, et al. Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferon-gamma. Invest Ophthalmol Vis Sci. 2007;48:2553-2560.
50. Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009; 54:321-338.
51. Dogru M, Tsubota K. Pharmacotherapy of dry eye. Expert Opin Pharmacother. 2011;12:325-334.
52. Li DQ, Luo L, Chen Z, et al. JNK and ERK MAP kinases mediate induction of IL-1b, TNF-a, and IL-8 following hyperosmolar stress in human limbal epithelial cells. Exp Eye Res. 2006;82: 588-596.
53. Solomon A, Dursun D, Liu Z, et al. Pro-and anti-inflammatory formsof interleukin-1 in tearfluidand conjunctiva ofpatientswith dry-eye disease. Invest Ophthalmol Vis Sci. 2001;42:2283-2292.
54. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6:772-783.
55. Folco EJ, Rocha VZ, Ĺopez-Ilasaca M, et al. Adiponectin inhibits pro-inflammatory signaling in human macrophages independent of interleukin-10. J Biol Chem. 2009;284:25569-25575.
56. Chandrasekar B, Boylston WH, Venkatachalam K, et al. Adiponectin blocks interleukin-18-mediated endothelial cell death via APPL1-dependent AMP-activated protein kinase (AMPK) activation and IKK/NF-kappaB/PTEN suppression. J Biol Chem. 2008;283:24889-24898.
57. Stern ME, Gao J, Siemasko KF, et al. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res. 2004;78:409-416.
58. Pitcher JD III, De Paiva CS, Pelegrino FS, et al. Pharmacological cholinergic blockade stimulates inflammatory cytokine production and lymphocytic infiltration in the mouse lacrimal gland. Invest Ophthalmol Vis Sci. 2011;52:3221-3227.
59. Song XJ, Li DQ, Farley W, et al. Neurturin-deficient mice develop dry eye and keratoconjunctivitis sicca. Invest Ophthalmol Vis Sci. 44:4223-4239.
60. Zhang X, ChenW, De Paiva CS, et al. Interferon-c exacerbates dry eye-induced apoptosis in conjunctiva through dual apoptotic pathways. Invest Ophthalmol Vis Sci. 2011;5:6279-6285.
61. de Paiva CS, Schwartz CE, Gjörstrup P, et al. Resolvin E1 (RX-10001) reduces corneal epithelial barrier disruption and protects against goblet cell loss in a murine model of dry eye. Cornea. 2012;31:1299-1303.
62. Choi W, Li Z, Oh HJ, et al. Expression of CCR5 and its ligands CCL3,-4, and-5 in the tear film and ocular surface of patients with dry eye disease. Curr Eye Res. 2012;37:12-17.
63. De Paiva CS, Hwang CS, Pitcher JD III, et al. Age-related T-cell cytokine profile parallels corneal disease severity in Sjogren's syndrome-like keratoconjunctivitis sicca in CD25KO mice. Rheumatology (Oxford). 2010;49:246-258.